Table 2.
Age-specific vaccine effectiveness of confirmed measles cases. Borno, December 2018 – March, 2019
| Age Group | Vaccinated cases | Confirmeda cases | PCV (95% CI) | PPV | VE % (95% CI) |
|---|---|---|---|---|---|
| < 9 monthsb | 1 | 49 | 0.02 (0.00–0.11) | 0.00 | – |
| 9–11 months | 7 | 42 | 0.17 (0.07–0.31) | 0.61 | 87.3 (71.0–95.2) |
| 12–23 months | 9 | 118 | 0.08 (0.04–0.14) | 0.69 | 96.2 (92.6–98.3) |
| 24–35 months | 12 | 97 | 0.12 (0.07–0.21) | 0.84 | 97.3 (95.1–98.7) |
| 36–47 months | 5 | 75 | 0.07 (0.02–0.15) | 0.84 | 98.6 (96.7–99.6) |
| 48–59 months | 10 | 49 | 0.20 (0.10–0.34) | 0.70 | 89.2 (77.9–95.2) |
| 60–71 months | 3 | 38 | 0.08 (0.02–0.21) | 0.94 | 99.5 (98.3–99.9) |
| Overall | 47 | 468 | 0.10 (0.07–0.13) | 0.88 | 98.4 (97.8–98.8) |
PCV Proportion of cases vaccinated, PPV Proportion of the population vaccinated based on 2018 PCCS report, VE Vaccine effectiveness, CI Confidence Interval.
aCases reported from IDP camps were excluded from the VE estimation as the PCCS did not capture coverage from IDP camps
bThe < 9 month old infants were not scheduled for measles vaccination and were excluded from the VE estimation